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Abstract
Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a major global health problem, despite the widespread use
of the M. bovis Bacille Calmette-Guerin (BCG) vaccine and the availability of drug therapies. In recent years, the high
incidence of coinfection of M. tuberculosis and HIV, as well as escalating problems associated with drug resistance, has raised
ominous concerns with regard to TB control. Vaccination with BCG has not proven highly effective in controlling TB, and
also has been associated with increasing concerns about the potential for the vaccine to cause disseminated mycobacterial
infection in HIV infected hosts. Thus, the development of an efficacious and safe TB vaccine is generally viewed as a critical
to achieving control of the ongoing global TB pandemic. In the current study, we have analyzed the vaccine efficacy of an
attenuated M. tuberculosis strain that combines a mutation that enhances T cell priming (DsecA2) with a strongly
attenuating lysine auxotrophy mutation (DlysA). The DsecA2 mutant was previously shown to be defective in the inhibition
of apoptosis and markedly increased priming of antigen-specific CD8
+ T cells in vivo. Similarly, the DsecA2DlysA strain
retained enhanced apoptosis and augmented CD8
+ T cell stimulatory effects, but with a noticeably improved safety profile
in immunosuppressed mice. Thus, the M. tuberculosis DsecA2DlysA mutant represents a live attenuated TB vaccine strain
with the potential to deliver increased protection and safety compared to standard BCG vaccination.
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Introduction
Tuberculosis is a devastating disease, and despite the availability
of therapeutic drugs and widespread vaccination with BCG, it
remains a serious global health issue, infecting nearly a third of the
world population and causing 2–3 million deaths annually [1].
Since initiating BCG vaccination in the 1920s, more than three
billion people have been vaccinated with BCG [2]. However, the
benefits and drawbacks of BCG have been debated since its early
use. Ongoing concerns and controversies include the potential for
disseminated infection by BCG in immunosuppressed hosts, loss of
sensitivity to tuberculin as a diagnostic reagent, and the failure of
BCG to show efficacy in the prevention of pulmonary TB in a
number of trials in developing countries [3,4,5]. There have been
numerous hypotheses to explain the inadequate protective effect of
BCG against pulmonary TB. Factors related directly to the
vaccine, such as inappropriate treatment and storage of the
vaccine and strain variability have been suggested. Additionally,
several deficits of a more fundamental immunological character
have been proposed, such as a lack of important antigens,
interaction with environmental mycobacteria, and dwindling
efficacy of BCG vaccination over time [6,7]. Because various T
cell subsets have been shown to participate in the immune
responses against mycobacteria, the lack of an effective stimulation
of the optimal blend of T cell populations, and particularly the
failure to induce CD8
+ T cells, may also explain the insufficient
levels of immunity promoted by the BCG vaccine strains [7,8]. In
fact, increased vaccine efficacy against tuberculosis has been
observed in association with enhanced priming of CD8
+ T cells in
vivo [9,10]. As there is an urgent need for innovative protective
vaccine strategies, we must identify and exploit the mechanisms
that can facilitate or inhibit immunity to M. tuberculosis, while
simultaneously maintaining an adequate safety profile.
In previous work, we described a novel immune-evasion
strategy of M. tuberculosis by which secretion of superoxide
dismutase A (SodA) inhibits the apoptotic program of infected
macrophages, effectively blunting the specific CD8
+ T-cell
responses to the bacterium. In those studies, inactivation of the
M. tuberculosis secA2 gene, which encodes a virulence-associated
protein secretion system, enhanced the apoptosis of infected
macrophages and increased priming of antigen-specific CD8
+ T
cells in vivo. Vaccination of mice and guinea pigs with the DsecA2
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15857mutant significantly increased resistance to virulent M. tuberculosis
challenge [9]. Thus, inactivation of the secA2 gene represents a
novel way to improve the immunogenicity of mycobacterial
vaccines. However, in subsequent studies we observed that
inactivation of secA2 in BCG did not lead to enhanced
immunogenicity (unpublished data) and the DsecA2 mutant
retained a moderate level of virulence, making it unsuitable as a
vaccine. In order to improve vaccine efficacy and safety of the
DsecA2 mutant, we generated multiple double and triple mutants
of the DsecA2 mutant strain via incorporation of other attenuating
mutations of M. tuberculosis. In the current study, we have evaluated
one of the double mutants, DsecA2DlysA, and show here that this
strain displays an excellent safety profile in immunocompromised
SCID mice while retaining the enhanced immunogenicity of the
parental DsecA2 mutant strain.
Results
Improved attenuation of M. tuberculosis DsecA2DlysA in
SCID mice
The principal advantage of incorporating auxotrophic muta-
tions into vaccine candidates is the associated reduction in
virulence. Previously, the DlysA strain of M. tuberculosis was shown
to be unable to replicate in vitro in the absence of lysine
supplementation of the growth medium, and to be markedly
attenuated for growth in vivo in SCID mice, consistent with the
inability of the bacteria to scavenge sufficient lysine from the
intracellular environment [11,12]. Strain DsecA2DlysA is strictly
auxotrophic for lysine, and no growth of the mutant was observed
in the absence of lysine supplementation. To investigate the
virulence of the double mutant, SCID mice were injected
intravenously with 10
5 CFU of either wild-type M. tuberculosis
(strain H37Rv), a DsecA2 mutant, or a double mutant strain
DsecA2DlysA. As expected, the DsecA2 single mutant of M.
tuberculosis showed a high level of virulence in this experiment, as
all animals died in less than 50 days. In contrast, a significant
reduction of virulence of the DsecA2DlysA strain was observed, as
the group infected with this strain had a median survival of .300
days. In comparison, BCG infected SCID mice showed a median
survival of ,150 days, and all BCG infected animals succumbed
by day 165 (Figure 1). These data clearly indicated that
DsecA2DlysA was strongly attenuated and even less virulent than
the standard BCG vaccine strain in the context of severe
immunodeficiency.
Induction of macrophage apoptosis by M. tuberculosis
DsecA2DlysA
The secA2 gene encodes an accessory secretion factor required
for the export of superoxide dismutase protein (SodA), an enzyme
that catalyzes conversion of superoxide anions to hydrogen
peroxide. In previous work we have shown that deletion of secA2
gene results in enhanced apoptosis of infected macrophage, an
effect that was reversed by the restoration of secretion of SodA
through a secA2 independent pathway [9]. To test whether the
DsecA2DlysA has retained this pro-apoptotic property, transformed
human monocyte/macrophage cells (THP-1 cells) were infected
with at an MOI of 10 bacilli per macrophage with H37Rv, DsecA2,
DlysA,o rDsecA2DlysA. At 72 hours following infection, quantita-
tive assessment of apoptosis by staining for DNA strand breakage
(TUNEL) showed that both DsecA2 and DsecA2DlysA demonstrated
high levels of apoptosis, whereas WT M. tuberculosis and the single
mutant auxotroph DlysA did not (Figure 2). These results indicated
that the defect in apoptosis inhibition resulting from the loss of
DsecA2 was retained in the DsecA2DlysA double mutant.
Augmented CD8
+ T cell priming following immunization
with DsecA2DlysA
As illustrated in earlier work, an important consequence of
blocking apoptosis is an effective reduction of the priming of CD8
+ T
cell response to M. tuberculosis. M. tuberculosis antigens are produced
within a phagosomal compartment which is sequestered from the
classical cytoplasmic pathway of antigen processing. As with other
vacuolar pathogens, such as Salmonella, display of these antigens on
MHC class I molecules likely occurs by the uptake and presentation
of apoptotic material by bystander dendritic cells (DC) [13].
Consistent with this idea, we have previously shown that mice
vaccinated with the DsecA2 mutant strain exhibited a marked
enhancement of CD8
+ T cell priming. To test whether the
DsecA2DlysA mutant strain retained the enhanced immunogenicity
observed in the parental DsecA2 strain, we used a CD8
+ Tc e l l
adoptive transfer strategy similar to that described previously [9].
Recipient mice injected with low numbers (5610
5)o fO T - ITc e l l s
were vaccinated subcutaneously with recombinant M. tuberculosis
strains expressing the 19-kDa lipoprotein-SIINFEKL fusion protein.
This experimental design enabled accurate quantification of antigen-
specific CD8
+ T cells by tetramer staining in mice vaccinated with
H37Rv-OVA,DsecA2-OVA, DlysA-OVA, and DsecA2DlysA-OVA. As
anticipated, mice vaccinated with H37Rv-OVA and DlysA-OVA
showed little detectable expansion of transferred T cells, while the
pro-apoptotic strains, DsecA2-OVA, and DsecA2DlysA-OVA induced
significant expansion of antigen specific CD8
+Tc e ll s( F i g u r e3 A ) .We
also measured expression of CD62 ligand (CD62L) and CD44 on
tetramer





high), and effector memory cells
(CD44
highCD62L
low). Our results showed enhanced expansion of
both subsets in mutant strains deficient in secA2( F i g u r e3 B ,C ) .I n
addition, we were able to demonstrate a measurable induction of
endogenous CD8
+ T cells in mice vaccinated intravenously with
DsecA2-OVA and DsecA2DlysA-OVA, with little detectible expansion
of tetramer positive cells in mice vaccinated with H37Rv-OVA and
DlysA-OVA (Figure 4).
Figure 1. Survival of immunocompromised mice after infection
with virulent M. tuberculosis, DsecA2, DsecA2DlysA, or BCG. SCID
mice were infected intravenously with 10
5 CFUs of virulent M.
tuberculosis (H37Rv), M. tuberculosis DsecA2, BCG Pasteur, or M.
tuberculosis DsecA2DlysA. Mice were followed for survival, or were
sacrificed humanely when moribund.
doi:10.1371/journal.pone.0015857.g001
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challenge following vaccination with DsecA2DlysA
Asdiscussed above,althoughDlysA has a compelling safetyprofile
in immunocompromised animals, and performs much better than
BCG in our studies conducted in SCID mice, its poor growth in vivo
comes at the cost of weaker immunogenicity. In order to determine
whether the enhanced T cell priming observed with DsecA2DlysA
correlated with improved performance as a live vaccine strain, we
conducted immunization and challenge studies designed to evaluate
potential vaccine efficacy of the double mutant. C57BL/6 mice that
were either naive or immunized 8 weeks earlier by subcutaneous
immunization with live DsecA2DlysA, DsecA2 or BCG (Pasteur strain)
were challenged by low-dose aerosol infection with virulent M.
tuberculosis (Erdman). In naive mice, substantial growth in the lungs
and dissemination to spleens were detected within 1 month of
challenge. In contrast, vaccination with DsecA2DlysA, DsecA2 and
BCG considerably reduced M. tuberculosis bacillary loads in both
lungs and spleens of aerosol-challenged mice as compared with
naive controls (Figure 5A).
Immunization with DsecA2 and DsecA2DlysA also showed a more
prolonged effect on control of M. tuberculosis infection, which was
still apparent 3 months after challenge. More importantly, the
protection evoked by DsecA2DlysA immunization was significantly
greater than that obtained with BCG vaccination, as measured by
bacterial burden in both the lung and spleen at 3 months post
challenge (0.66-log reduction in lungs of DsecA2DlysA versus BCG
vaccinated mice; P,0.001, 0.68-log reduction in spleens DsecA2-
DlysA versus BCG vaccinated mice; P,0.01). Interestingly,
DsecA2DlysA vaccinated mice also showed significantly lower lung
bacillary loads than mice vaccinated with DsecA2 (0.35-log
reduction in lungs of DsecA2DlysA versus DsecA2 vaccinated mice;
P,0.05) (Figure 5A), an effect that may relate to the enhanced
stability of memory cells in response to non-persistent live vaccines
[14,15,16]. The one month time point represents the peak
bacillary burden and the 3 month time point represents the set
point of the bacillary burden in the chronic phase of infection.
Histopathological examination of the lungs from mice immunized
with BCG, DsecA2, or DsecA2DlysA showed relatively mild inflam-
mation with less severe spreading lung lesions, less extensive
granulomatous pneumonia, and reduced consolidation compared
with naive mice (Figure 5B).
Discussion
In recent years a number of attenuated strains of M. tuberculosis,
many constructed through the engineered deleting of genes
important for growth in vivo, have been shown to confer
protection against challenge with virulent M. tuberculosis [17,18].
The appeal of auxotrophic mutant strains, from the standpoint of
vaccine development, relates to their marked growth attenuation in
vivo and exceptional safety profile in immunocompromised
animals. However, a significant drawback of many of these strains
is poor immunogenicity in immunocompetent animals, which
appears to be a function of reduced growth and decreased antigen
load. Consistent with this view, the DlysA mutant strain, while
shown to be profoundly attenuated in SCID mice, required
multiple rounds of immunization to achieve levels of protection
comparable to BCG in immunocompetent mice [19]. In contrast,
we have shown in the current study that a single immunization
with the DsecA2DlysA strain conferred markedly enhanced
protection from challenge with virulent M. tuberculosis when
compared to BCG. A similar result was previously observed for
the parental DsecA2 strain, which exhibited enhanced CD8
+ T cell
priming when compared with wild-type M. tuberculosis, while
conferring enhanced protection to vaccinated mice and guinea
pigs compared to BCG. Enhanced immunogenicity of DsecA2
correlated with the loss of apoptosis inhibition by the mutant
strain. This proapoptotic phenotype was preserved in the
DsecA2DlysA strain, along with the enhanced CD8
+ T cell
stimulating effect. In the present study, we confirmed our previous
finding that DsecA2 conferred enhanced protection against virulent
challenge when compared with BCG, and demonstrated that
vaccination with the DsecA2DlysA double mutant strain also gave
protection that was significantly better than that achieved with
BCG. In fact, DsecA2DlysA vaccination led to a significantly greater
Figure 2. Induction of apoptosis in macrophages by infection with M. tuberculosis DsecA2DlysA. Human THP-1 cells were infected with
wild type M. tuberculosis (H37Rv) or the M. tuberculosis mutant strains DsecA2, DlysA,o rDsecA2DlysA strains at an MOI of 10. Uninfected (UI) cells were
used as a control. Cells were stained after 72 hours infection for TUNEL and analyzed by FACS and representative histograms of TUNEL staining are
shown. Quantitation by FACS of cells positive for TUNEL is summarized in the graph. Asterisks indicate statistical significance compared to H37Rv
(F,p ,0.001; one-way ANOVA).
doi:10.1371/journal.pone.0015857.g002
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months, when compared with the parental DsecA2 strain.
The explanation for this augmented protective efficacy of
DsecA2DlysA vaccination may relate to the inability this strain to
persist in vivo, leading to more rapid antigen clearance after T cell
priming and more stable memory T cell populations [20]. This is a
substantial difference from the parental DsecA2 single mutant,
which is known to be only moderately attenuated for growth in
mice and most likely persists at least at low levels for many weeks
and perhaps permanently [21]. Research on T cell responses to
viral pathogens including LCMV, Hepatitis C, and SIV, suggests
that the persistence of antigen stimulation associated with chronic
infection can lead to the functional impairment or ablation of
effector and memory CD8
+ T cell responses. In this model, too
little antigen leads to suboptimal responses, whereas an over-
abundance or prolonged expression of antigen leads to a
suboptimal reservoir of memory T cells [22,23,24,25]. Through
the pairing of the augmented CD8+ T cell priming properties of
the DsecA2 mutation with the restrained growth imparted by DlysA,
we may have achieved a more favorable formulation to generate
robust, yet stable, memory responses in vaccinated animals.
A salient advantage of the auxotrophic double mutant,
illustrated here, is its marked attenuation in immunocompromised
mice. Due to the high incidence of HIV-infection in regions where
TB is endemic, safety of immunocompromised animal models has
become an important consideration for experimental vaccines.
Even BCG, widely regarded as a safe vaccine, has been shown to
progress to disease in a significant subpopulation of HIV infected
individuals. In a study of BCG vaccinated HIV-positive children
conducted in 2003, 10% of mycobacterial disease was attributed to
BCG [26]. HIV infection leads to a disproportionate loss of CD4
+
T cells, which in experimental models have been shown to be
essential for controlling infection with BCG [27]. Although CD4
+
T cells are critical for protective anti-TB protective immunity [28],
CD8
+ T cells have been shown to play an important role in the
control of TB, particularly in CD4-deficient mice [5,6,29]. Thus,
the DsecA2DlysA strain, with an improved safety profile and
augmented CD8
+ T cell immunogenicity, may serve as an effective
substitute for BCG in the HIV infected population.
Consistent with results from our previous work characterizing
the immunogenicity of DsecA2, the mechanisms underlying the
augmented vaccine properties of DsecA2DlysA appear to stem, at
Figure 3. Augmented memory T cell populations following immunization with M. tuberculosis DsecA2DlysA. C57BL/6 mice were injected
intravenously with 5610
5 OT-I splenocytes 24 hours prior to subcutaneous immunization with either mycobacteria expressing OVA. The animals
were sacrificed 5 weeks post immunization, and splenocytes were stained for five color fluorescence analysis by flow cytometry using antibodies
specific for Thy1.2, B220, CD62L and CD44 plus SIINFEKL-loaded H-2K
b tetramer. (A) FACS analysis of total B220 negative events among 1.5610
6 total
lymphocytes, showing proportions of Thy1.2
+ cells staining with tetramer (circled). (B) Dot plots show expression of CD44 and CD62L on cells gated
for tetramer staining as in (A) from representative mice infected with the indicated bacterial strains. (C) The graph shows percentages of tetramer
positive cells expressing either high levels of CD62L (central memory T cells) or low levels of CD62L (effector memory T cells).
doi:10.1371/journal.pone.0015857.g003
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+ T
cell priming and memory T cell generation. In addition, by
coupling the moderately attenuating DsecA2 mutation with DlysA
we were not only able to achieve a superior safety profile, but also
significantly improved control of infection relative to the parental
strain. The rational design of novel, live attenuated vaccines for
Figure 4. Enhanced priming of endogenous SIINFEKL-specific CD8
+ T cells following immunization with DsecA2DlysA. The frequencies
of SIINFEKL-specific CD8
+ T cells in spleens from mice infected with the indicated strains of M. tuberculosis were determined. The percentage of CD8
+
cells staining with SIINFEKL-loaded H-2K
b tetramers and representative FACS plots are shown for cohorts of four mice that were analyzed 7 days after
intravenous infection. Asterisks indicate statistical significance compared to Rv-ova (* ,0.05; one-way ANOVA test).
doi:10.1371/journal.pone.0015857.g004
Figure 5. Protective immunity against virulent M.tuberculosis challenge in mice following vaccination with DsecA2DlysA. (A) C57BL/6
mice were vaccinated subcutaneously with saline (naı ¨ve) or with 1610
6 BCG, M. tuberculosis DsecA2 or DsecA2DlysA. All mice were challenged by aerosol 2
months later with 50–100 CFU of virulent M. tuberculosis (Erdman strain). Graphs show means and standard errors of colony forming units (CFU) of
M. tuberculosis in lungs and spleens at 1 and 3 months after challenge for groups of five mice. Asterisks indicate statistical significance compared to
unvaccinated groupor between bracketed groups (*, p,0.05;**, p,0.01; F, p,0.001;two-way ANOVA). (B) Lungs of mice vaccinated andchallenged with
virulent M. tuberculosis as in (A) were examined histologically at 1 month and 3 months post-challenge. More severe spreading lung lesions with extensive
granulomatous pneumonia and consolidation were observed in unvaccinated mice as compared to mice vaccinated with BCG, DsecA2,o rDsecA2DlysA.
doi:10.1371/journal.pone.0015857.g005
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gen virulence strategies. This study clearly demonstrates a proof of
this principle by combining DsecA2 with a second mutation that
interferes with virulence of M. tuberculosis, thus generating a novel
attenuated candidate mycobacterial vaccine strain with signifi-
cantly improved safety and efficacy.
Materials and Methods
Bacterial strains and growth media
Virulent M. tuberculosis strains H37Rv (obtained from Trudeau
Institute), Erdman, M. tuberculosis DsecA2 mutant (mc
23112), and
DlysA have been described previously [30]. M. tuberculosis strains
were grown on Middlebrook 7H9 broth or 7H10 agar containing
10% (vol/vol) oleic acid–albumin-dextrose-catalase (OADC; BD
Diagnostics-Diagnostic Systems), 0.5% glycerol, and 0.05% (vol/
vol) Tween-80. For DlysA and DsecA2lysA, the culture medium was
supplemented with L-lysine (80 mg/ml). The E. coli strain DH5a
was used for cloning purposes and grown on Luria-Bertani agar or
broth (Fisher Scientific) at 37uC. Ampicillin (50 mg/ml), hygro-
mycin (50 mg/ml for mycobacterial selection or 150 mg/ml for E.
coli), and kanamycin (20 mg/ml for mycobacterial selection or
40 mg/ml for E. coli) were used to select for recombinant strains.
Construction of recombinant mycobacterial strains
The double mutant strain DsecA2DlysA was constructed using
specialized transduction to disrupt the chromosomal copy of the
lysA gene of an unmarked secA2 clone, as described [30]. To
generate OVA expressing strains of wild type M. tuberculosis
(H37Rv-OVA) or of mutants (DsecA2-OVA, DlysA-OVA, and
DsecA2DlysA-OVA), the wild type and mutant strains were
transformed with the plasmid p19OVA which encodes the M.
tuberculosis 19kD lipoprotein fused at the C-terminus with the
sequence for ovalbumin that includes the MHC class I presented
epitope SIINFEKL [9]. Transformations of M. tuberculosis were
performed according to a published protocol [31].
Apoptosis studies in THP-1 cells
THP-1 cells (ATCC) were grown in RPMI-1640 (Gibco BRL;
Invitrogen) supplemented with 10% FBS, 1% HEPES, 1%
nonessential amino acids and essential amino acids. THP-1 cells
were treated with 8 ng/ml PMA (Sigma-Aldrich) in order to
induce differentiation into macrophage-like cells. Differentiated
THP-1 cells were plated in 6-well plates at 2610
6 cells per well
and allowed to adhere overnight. Dispersed bacilli were incubated
with cells for 3 hours using a multiplicity of infection (MOI) of 10
bacteria to 1 THP-1 cell. The cells were then washed twice with
PBS and incubated at 37uC in a 5% CO2 incubator for 72 hours.
The presence of apoptotic cells in the cell cultures was analyzed
with In Situ Cell Death Detection Kit, Fluorescence (Roche
Diagnostics), following the manufacturer’s instructions.
T cell activation studies
C57BL/6 mice received 5610
5 splenocytes from OVA-specific
TCR transgenic OT-1 mice (Taconic/National Institute of Allergy
and Infectious Diseases [NIAID]) intravenously, and then infected
subcutaneously 24 hours later with 1610
6 CFU H37Rv-OVA,
DsecA2-OVA, DlysA-OVA, or DsecA2DlysA-OVA. At 5 weeks post
immunization, splenocytes were isolated and stained with PE-
labeled peptide-loaded (SIINFEKL) H-2K
b tetramers in combi-
nation with antibodies specific to Thy1.2, CD44, CD62L and
B220 (all antibodies were purchased from BD Biosciences).
Percentages of lymphocytes stained with tetramer and expressing





low) memory cells were determined by flow
cytometry. For detection of endogenous OVA responsive T cells,
mice were infected intravenously with 1610
7 CFU H37Rv-OVA,
DsecA2-OVA, DlysA-OVA, or DsecA2lysA-OVA. After 7 days
splenocytes were isolated and stained with PE-labeled peptide-
loaded (SIINFEKL) H-2K
b tetramers in combination with
antibodies specific to CD8.
Vaccination and challenge studies
All animal studies were approved by the institutional animal
care and use committees of the Albert Einstein College of
Medicine (A3312-01), the Center for Biologics Evaluation and
Research, and the Duke University (A071-10-03). C57BL/6 mice
were vaccinated subcutaneously with 1610
6 CFU of M. tuberculosis
DsecA2, DsecA2DlysA,o rM. bovis BCG-Pasteur as described
previously [32]. Aerogenic challenge was performed 2 months
later using a Glas-Col inhalation chamber to deliver 50–100 CFU
per animal of M. tuberculosis Erdman strain. Mice were sacrificed at
1 and 3 months after challenge. Lungs and spleens of individual
mice were aseptically removed and homogenized separately in
5 ml normal saline plus 0.05% Tween-80 using a Seward
Stomacher 80 blender (Tekmar). The homogenates were diluted
serially and plated on Middlebrook 7H10 agar. Lung tissues were
processed for histopathology using standard paraffin fixation,
sectioning, and H&E staining. In the survival study, animals
infected with M. tuberculosis Erdman were observed daily until they
died or became moribund and were euthanized.
Statistics
Two-way ANOVA with Bonferroni’s post test and one-way
ANOVA with the Tukey post test were used for analyses using
GraphPad Prism version 5 for Windows (GraphPad; [www.
graphpad.com]). P values of less than 0.05 were considered
significant.
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